Evotec

EQS-News: Just – Evotec Biologics awarded contract from the U.S. Department of Defense under accelerated antibodies program

Retrieved on: 
Tuesday, September 20, 2022

Just Evotec Biologics awarded contract from the U.S. Department of Defense under accelerated antibodies program

Key Points: 
  • Just Evotec Biologics awarded contract from the U.S. Department of Defense under accelerated antibodies program
    The issuer is solely responsible for the content of this announcement.
  • Plague, an infectious disease caused by the bacterium Yersinia pestis (Y. pestis), is one of the designated targets of interest under the DODs Accelerated Antibodies Program.
  • The advanced Just Evotec Biologics platform is specifically well suited for monoclonal antibodies as well as other protein modalities such as Fc fusion proteins.
  • Just Evotec Biologics J.POD Redmond, Washington biologics development and cGMP manufacturing facility will develop mAb-based drug products for the US Department of Defense.

DGAP-News: Evotec initiates ground-breaking for new biologics facility J.POD® Toulouse, France (EU)

Retrieved on: 
Friday, September 16, 2022

Evotec initiates ground-breaking for new biologics facility J.POD Toulouse, France (EU)

Key Points: 
  • Evotec initiates ground-breaking for new biologics facility J.POD Toulouse, France (EU)
    The issuer is solely responsible for the content of this announcement.
  • J.POD Toulouse, France (EU), the second facility of its kind and the first one on European ground, will employ Just Evotec Biologics flexible J.POD technology to deliver much-needed clinical and commercial manufacturing capacity for biologics.
  • Just Evotec Biologics opened the first facility of this kind, J.POD Redmond, WA (US), in August 2021.
  • Dr Craig Johnstone, Chief Operating Officer of Evotec, commented: Todays ground-breaking for J.POD Toulouse, France (EU), Just Evotec Biologics second J.POD facility, marks an important milestone on our path to making biologics globally available.

Sernova Announces the Appointment of Daniel Mahony, Ph.D. to its Board of Directors

Retrieved on: 
Wednesday, September 7, 2022

LONDON, Ontario, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in regenerative medicine cell therapeutics, today announced the appointment of Daniel Mahony, Ph.D. to its Board of Directors, effective September 30th, 2022. Dr. Mahony is Entrepreneur-in-Residence at Evotec and is also responsible for managing Evotec’s equity investment portfolio.

Key Points: 
  • We are delighted to welcome Dr. Mahony to Sernovas Board of Directors, said Frank Holler, Executive Chair of Sernova.
  • This background gives him deep insights into the healthcare business and capital markets which will be very valuable for Sernova.
  • Dr. Mahony stated, Sernova is uniquely well positioned with its Cell Pouch System to become a leading player in regenerative medicine.
  • This collaboration potentially provides Sernova an unlimited supply of insulin-producing cells to treat millions of patients with insulin-dependent diabetes (type 1 and type 2).

Sernova Receives Second Tranche Equity Investment from Evotec of $6.8 Million at a Price of $2.50 Per Share

Retrieved on: 
Thursday, September 1, 2022

Upon completion of the second tranche, Evotecs strategic investment in Sernova totals $27,098,000.

Key Points: 
  • Upon completion of the second tranche, Evotecs strategic investment in Sernova totals $27,098,000.
  • Evotecs investment at $2.50 per share, significantly more than double yesterdays closing price, reflects the value our strategic partner places on Sernova relative to the current trading price on the TSX, commented Dr. Philip Toleikis, President and CEO of Sernova Corp.
  • The dedication and synergy of our mutual teams to advance the iPSC diabetes program expeditiously has been impressive.
  • In May 2022, Sernova and Evotec entered into a global strategic collaboration to develop an implantable off-the-shelf iPSC-based (induced pluripotent stem cells) beta cell replacement therapy.

DGAP-News: Evotec expands clinical and commercial drug substance manufacturing with acquisition of Central Glass Germany

Retrieved on: 
Thursday, August 25, 2022

60 CHEMISTS

Key Points: 
  • 60 CHEMISTS
    Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced today that the Company expands its clinical and commercial manufacturing platform for small molecule therapeutics by acquiring Central Glass Germany GmbH from the Japanese chemical manufacturing company Central Glass Co. Ltd.
  • Going forward, Central Glass Germany GmbH will operate as Evotec Drug Substance (Germany) GmbH (Evotec DS).
  • The facility is EU cGMP certified and provides highly flexible drug substance manufacturing space with over 5,000 square meters of floor space.
  • The acquisition of the Central Glass site in Germany enhances and accelerates Evotecs strategy of pursuing integrated discovery and development of new medicines that matter.

DGAP-News: Just – Evotec Biologics and Alpine Immune Sciences expand partnership for commercial process development of ALPN-303

Retrieved on: 
Wednesday, August 10, 2022

Under the expanded contract, Just Evotec Biologics will leverage its data-driven technology platform to develop a commercial manufacturing process for ALPN-303.

Key Points: 
  • Under the expanded contract, Just Evotec Biologics will leverage its data-driven technology platform to develop a commercial manufacturing process for ALPN-303.
  • Commercial process development activities will be performed at Just Evotec Biologics state-of-the art J.POD biomanufacturing facility located in Redmond, Washington.
  • We are excited to be leveraging Just Evotec Biologics J.DESIGN platform to bring this important therapeutic to late-stage clinical development.
  • Just Evotec Biologics, wholly owned by Evotec SE, is a unique platform company that integrates the design, engineering, development, and manufacture of biologics.

Just – Evotec Biologics and Alpine Immune Sciences Expand Partnership for Commercial Process Development of ALPN-303

Retrieved on: 
Wednesday, August 10, 2022

Commercial process development activities will be performed at Just Evotec Biologics state-of-the art J.POD biomanufacturing facility located in Redmond, Washington.

Key Points: 
  • Commercial process development activities will be performed at Just Evotec Biologics state-of-the art J.POD biomanufacturing facility located in Redmond, Washington.
  • We are excited to be leveraging Just Evotec Biologics J.DESIGN platform to bring this important therapeutic to late-stage clinical development.
  • Just Evotec Biologics, wholly owned by Evotec SE, is a unique platform company that integrates the design, engineering, development, and manufacture of biologics.
  • The Alpine logo is a registered trademark or trademark of Alpine Immune Sciences, Inc. in various jurisdictions.

Chinook Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results

Retrieved on: 
Monday, August 8, 2022

SEATTLE, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today provided a business update and reported financial results for the quarter and six months ended June 30, 2022.

Key Points: 
  • SEATTLE, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today provided a business update and reported financial results for the quarter and six months ended June 30, 2022.
  • During the second quarter of 2022, we executed well on advancing our pipeline of clinical and preclinical programs for rare, severe chronic kidney diseases.
  • Chinook plans to report additional data from the AFFINITY trial in the second half of 2022, as well as during 2023.
  • We paid this milestone, net of taxes and expenses, to the CVR holders in the second quarter of 2022.

DGAP-News: Evotec, Boehringer Ingelheim, and bioMérieux launch Aurobac, a joint venture to fight Antimicrobial Resistance

Retrieved on: 
Wednesday, July 6, 2022

We are excited to launch Aurobac together with our partners at Boehringer Ingelheim and bioMrieux, to combine our complementary strengths.

Key Points: 
  • We are excited to launch Aurobac together with our partners at Boehringer Ingelheim and bioMrieux, to combine our complementary strengths.
  • We supply the most comprehensive integrated diagnostic solutions to support an appropriate use of antibiotics (antimicrobial stewardship), said Alexandre Mrieux, bioMrieux Chairman and CEO.
  • Our role within the joint venture is to develop and commercialize diagnostic tests, including Companion Diagnostics, which deliver rapid, reliable and actionable results.
  • bioMrieux has over 55 years of diagnostics expertise with more than 75% of its research and development budget focused on antimicrobial resistance.

Boehringer Ingelheim, Evotec and bioMérieux launch Aurobac, a joint venture to fight Antimicrobial Resistance

Retrieved on: 
Wednesday, July 6, 2022

The aspiration is to succeed in the fight against AMR, which is a major public health threat.

Key Points: 
  • The aspiration is to succeed in the fight against AMR, which is a major public health threat.
  • The rise of antibiotic-resistant infections also called antimicrobial resistance, or AMR is indeed a looming global crisis, said Michel Pairet, Head of Boehringer Ingelheims Innovation Unit and Member of the Board of Managing Directors.
  • We are excited to launch Aurobac together with our partners at Boehringer Ingelheim and bioMrieux, to combine our complementary strengths.
  • bioMrieux has over 55 years of diagnostics expertise with more than 75 percent of its research and development budget focused on antimicrobial resistance.